This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Idenix Pharma: Guilty By Association

Stocks in this article: IDIX BMY

Unfortunately, I don't think the clinical hold on IDX-184 -- the company's lead drug and the key to investor confidence -- will be easy to remove. That means Idenix will likely be dead money near-term.

Here's why: FDA's concerns stem from a theoretical connection between the Idenix and Bristol-Myers compounds. Idenix hasn't seen any clinical cardiovascular toxicity or preclinical warning signs thus far, which makes it hard to reassure regulators that the risks are manageable. As the saying goes, it's difficult to "disprove a negative."

FDA has asked Idenix for new data, including preclinical studies and cardiac evaluations of existing patients. The company plans to submit this information by year-end, which means that investors should expect a response -- and, perhaps, a path forward -- during the first quarter of 2013.

FDA also wants Idenix to propose additional monitoring of IDX-184-treated patients for signs of cardiovascular toxicity in any new studies, but it's unclear which metrics would be useful. The company has started to explore a potential biomarker for cardiovascular toxicity -- the creatively named N-terminal prohormone of brain natriuretic peptide, or NT-proBNP -- but the impact of other drugs on NT-proBNP levels in hepatitis C patients makes definitive interpretations difficult.

Idenix is in a tough spot, and it's hard not to empathize with management. Nonetheless, until Bristol-Myers determines what caused the side effects associated with BMS-094, I don't foresee an expeditious path forward. Idenix does have other drugs in development, including the promising NS5A inhibitor IDX-719, but these will likely be overshadowed by the clinical hold on IDX-184. Given the potential for-tax loss selling as we approach year-end and the risk that the clinical hold on IDX-184 could remain unresolved until at least mid-2013, prudence dictates that investors wait on the sidelines for now.

Disclosure: Sadeghi has no positions in any of the stocks mentioned in this article.

Follow Nathan Sadeghi-Nejad on Twitter.

Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza's Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.
2 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs